ArticleDiscover nano2026
Enhanced plasmonic biosensors with machine learning for ultra-sensitive detection.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmonic biosensors, particularly Surface Plasmon Resonance and Surface-Enhanced Raman Spectroscopy, have gained significant attention for real-time, label-free biochemical detection. However, optimizing these sensors for maximum sensitivity and selectivity remains a challenge due to their complex plasmonic interactions with different biomolecules. This work proposes SERA, an AI driven framework that integrates machine learning algorithms with experimental Surface-Enhanced Raman Spectroscopy (SERS) data for the predictive modeling and optimization of plasmonic sensing performance. Using supervised learning techniques, the ML models are trained on a spectral dataset - SERS-DB obtained from various plasmonic nanostructures. The model predicts key parameters such as resonance shift, intensity variations, and molecular binding efficiency, allowing for rapid optimization of biosensor designs without extensive trial-and-error experimentation. This approach accelerates plasmonic biosensor development and enables real-time adaptive sensing based on live data. The results through evaluation on the SERS-DB database with 420 samples for training and 180 for the testing phase, 6 classes like Thiacloprid, Imidacloprid, Thiamethoxam, Nitenpyram, Tetrahydrofolate, and Dihydrofolate, an accuracy of 92%, precision & recall of 90%, and F1-score of 92% were attained. The SERA model excelled with an overall score of around 0.90 in all 6 classes, proving additional superiority in biosensing applications. Further comparative analysis of the proposed approach with conventional methods underscores the best performance in accuracy with 92%, sensitivity, 1000 nm/RIU, and 95% in optimization efficiency. Overall, this research highlights a scalable and cost-effective strategy for advancing biosensor technology in medical diagnostics, environmental monitoring, and bio photonics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.